Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab neoadjuvant chemo-immunotherapy plus surgery/CRT vs CRT then adebrelimab in stage III potentially resectable NSCLC
ChiCTR2500097905Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of adebrelimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: 2-year event-free survival rate. Started Feb 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500097905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097905.